Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence Testing in Idaho
Detection Principle
ImmunoAssay-Antibody
Target
IgG
Testing Method Category
Testing Method
Chemiluminescent microparticle immunoassay kit
Testing Method - Additional Info
Abbott SARS-CoV-2 IgG
Reported Performance
Specificity: 99.9% (1020 samples); Sensitivity: 100% (17dpo), 96.9% (14dpo), 82.4% (10dpo), 53.1% (7dpo), 100% (14 days post PCR positivity), 97.2% (10 days post PCR positivity), 88.7% (7 days post PCR positivity)
Sample Size
5901 samples (1020 serum samples before covid circulation, 125 positive, 4856 from another study)
Peer-reviewed
no
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements